
Cell Therapy
Characterisation
CMC
Regulatory & Standards
Reproducibility, Reliability, Robustness: Establishing Cornerstones for Standardisation Of Cell Manufacturing

Phacilitate
27 May 2020
SHARE NOW
Which manufacturing parameters have significant effects on product performance?
In the context of advanced therapeutic medicinal products, the ability to manipulate complex biological mechanisms provides therapy developers with a powerful tool to direct against various diseases.
However, to move forward and establish the true efficacy of cell therapies against specific indications, we must begin to understand which biological variables should be standardised to generate desired therapeutic outcomes.
In this on-demand webinar, we consider which manufacturing parameters have significant effects on product performance and suggest potential strategies to mitigate variability. There is also a discussion on the following:
- Minimising variability in cell manufacture
- The variability within the industry, such as groups manufacturing their own reagents and the need for potency assays
- The considerations for ancillary materials and the impact they can have on both process and product
- How should manufacturers evaluate these reagents to minimise variability of the final product?
- The variability of starting materials and hMSCs, how it impacts cell manufacturing and how to mitigate
More like this
Castle Creek Bioscience Achieves $112.8 Million Financing to Advance Gene Therapies
The late-stage cell and gene therapy company Castle Creek Biosciences has announced a $112.8 million preferred stock financing to advance the development and commercialization of gene therapies using their lentiviral platforms.
26 May 2022
Key Takeaways from ASGCT 2022
Ryan Leahy summarizes his key takeaways from his first Annual Meeting of the American Society for Gene and Cell Therapy.
25 May 2022
Umoja and Lupagen Collaboration Drives Improved Delivery for Next Generation in vivo CAR-T
The immune-oncology company Umoja Biopharma, has announced they have entered into collaboration with the gene therapy company Lupagen, who will support the administration of Umoja’s in vivo CAR-T cell therapeutic systems, to cancer patients, with their Side CAR-T ™ extracorporeal gene delivery system.
24 May 2022